Publication: Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model
| dc.contributor.author | Gimode, Winnie R | |
| dc.contributor.author | Kiboi, Daniel M | |
| dc.contributor.author | Kimani, Francis T | |
| dc.contributor.author | Wamakima, Hannah N | |
| dc.contributor.author | Burugu, Marion W | |
| dc.contributor.author | Muregi, Francis W | |
| dc.date.accessioned | 2016-04-29T09:08:26Z | |
| dc.date.available | 2016-04-29T09:08:26Z | |
| dc.date.issued | 2015 | |
| dc.description | Abstract | en_US |
| dc.description.abstract | Background: The evolution of drug-resistant parasites is a major hindrance to malaria control, and thus understanding the behaviour of drug-resistant mutants is of clinical relevance. The study aimed to investigate how resistance against lumefantrine (LU) and piperaquine (PQ), anti-malarials used as partner drugs in artemisinin-based combination therapy (ACT), impacts parasite fitness. This is important since resistance to ACT, the first-line anti-malarial regimen is increasingly being reported. | en_US |
| dc.identifier.uri | http://erepository.mku.ac.ke/handle/123456789/3849 | |
| dc.language.iso | en | en_US |
| dc.publisher | Gimode et al. Malaria Journal | en_US |
| dc.subject | Fitness cost, | en_US |
| dc.subject | Drug resistance | en_US |
| dc.subject | Piperaquine | en_US |
| dc.subject | Lumefantrine | en_US |
| dc.subject | Malaria | en_US |
| dc.subject | Correspondence | en_US |
| dc.title | Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication |